Thiazolidinediones (TZDs) are a new class of compounds that improve insulin sensitivity in type 2 diabetic patients as well as in rodent models of this disease. These compounds act as ligands for a member of the nuclear hormone receptor superfamily, peroxisome proliferator-activated receptor-␥ (PPAR-␥), which is highly expressed in adipose tissue and, moreover, has been shown to play an important role in adipocyte differentiation. The strong correlation between the antidiabetic activity of TZDs and their ability to activate PPAR-␥ suggests that PPAR-␥, through downstream-regulated genes, mediates the effects of TZDs. In this report, we present the isolation and characterization of 81 genes, encoding proteins of known function, differentially expressed during TZDstimulated differentiation of 3T3-L1 cells. By the use of different reverse-Northern blot techniques, the differential expression of 50 of these genes could be verified, and 21 genes were specifically regulated by a potent TZD during the course of adipocyte differentiation, whereas no effect of a PPAR-␥ antagonist could be observed in mature adipocytes. The differential expression of a large fraction of the isolated genes was also shown to occur in white adipose tissue of ob/ob mice treated with rosiglitazone; combined, our results suggest that an important effect of rosiglitazone in adipose tissue is based on activation of PPAR-␥ in preexisting preadipocytes found among the mature adipocytes, resulting in subsequent adipocyte differentiation.
T hiazolidinediones (TZDs) are a new class of compounds that improve the insulin sensitivity in type 2 diabetic patients as well as in rodent models of this condition. Repeated administration of TZDs to type 2 diabetic patients and insulinresistant KK and ob/ob mice, as well as Zucker fatty rats, has been shown to ameliorate hyperglycemia, hyperinsulinemia, and hyperlipidemia, thereby reversing, at least partially, the diabetic state (1, 2) .
TZDs are high-affinity ligands for peroxisome proliferator activated-receptor-␥ (PPAR-␥), which is a member of the nuclear hormone receptor superfamily (3) . PPAR-␥ forms heterodimers with members of the retinoid X receptor (RXR) family and regulates gene expression by binding to PPAR response elements in the promoter region of a variety of genes (4 -8) . Analyses of the PPAR-␥ expression pattern have revealed that the receptor is expressed abundantly in adipose tissue, and several observations suggest that PPAR-␥ is essential for adipocyte differentiation. First, forced expression of PPAR-␥ in fibroblasts leads to the development of an adipocyte phenotype, an event that is enhanced by the presence of ligands for this receptor (9) . Second, full or partial PPAR-␥ antagonists have recently been shown to prevent adipocyte differentiation in vitro (10 -13) . Third, a homozygous PPAR-␥ knockout mouse (PPAR-␥ Ϫ/Ϫ mouse) is completely devoid of adipose tissue (14) , heterozygotes (PPAR-␥ ϩ/Ϫ mice) are characterized by decreased adipose tissue mass (15) , and adipose tissue of mice chimeric for wild-type and PPAR-␥-null cells is composed exclusively of PPAR-␥ ϩ/ϩ cells (16) .
PPAR-␥ also seems to play a role in the development/ treatment of diabetes. Barroso et al. (17) recently identified a loss-of-function mutation in the human PPAR-␥ gene that is associated with severe insulin resistance. Moreover, a correlation between TZD potencies as antidiabetic agents in animal models and binding affinities to recombinant PPAR-␥ (18, 19) as well as binding affinities to differentiated 3T3-L1 cells and rat and human adipocytes has been observed (19, 20) . In addition, synthetic RXR agonists increase insulin sensitivity in obese mice and work in combination with TZDs to enhance antidiabetic activities (21) .
White adipose tissue (WAT) seems to play an essential role for glucose homeostasis, because transgenic mice lacking WAT are severely diabetic (22, 23) and WAT is required for the antidiabetic effect of TZDs (24) . In concert, these observations have led to the suggestion that the antidiabetic actions of the TZDs result from their ability to bind to and activate PPAR-␥ in adipose tissue. In contrast to these findings, it has been observed that heterozygous PPAR-␥-deficient mice are less susceptible to high-fat diet-or aging-induced insulin resistance than wild-type mice (15) . In addition, the Pro12Ala polymorphism in human PPAR-␥2, which moderately reduces the transcriptional activity of PPAR-␥, has been shown to confer resistance to type 2 diabetes (25) . This raises at least one unresolved issue: How can both PPAR-␥ activation and moderate PPAR-␥ reduction result in improved insulin resistance? Recent studies suggest that both states prevent adipocyte hypertrophy of existent adipocytes; heterozygous PPAR-␥ deficiency prevents it by decreasing lipogenesis, whereas TZDs stimulate adipocyte differentiation and apoptosis (26) . In line with these findings are several studies indicating that TZDs result in a relative increase of the number of smaller adipocytes (27, 28) .
To gain a detailed molecular understanding of the mechanism of action of TZDs, we have performed mRNA differential display analysis on differentiating 3T3-L1 cells and identified genes exhibiting altered expression after exposure to the potent TZD rosiglitazone. Furthermore, we have studied the importance of ligand-activated PPAR-␥ during the differentiation process as well as the influence of ligand-inactivated PPAR-␥ in mature adipocytes. Finally, we have analyzed the effect of rosiglitazone on the expression levels of the genes isolated by differential display in WAT, liver, and muscle of ob/ob mice.
tated by a PhosphoImager (Molecular Dynamics), and signals resulting from hybridization to a vector-specific PCR product were subtracted. DNA microarray analysis. All cDNA inserts from the differential display experiments were PCR-amplified using T7 and M13 reverse primers. PCR (100 l each) were purified using a Qiagen 96-well PCR purification system. The purified PCR products were mixed 1:1 in DMSO (Sigma) and spotted in duplicate onto silanized glass slides (Amersham Pharmacia Biotech) using an Amersham Pharmacia Biotech Generation III microarray spotter. All slides were UV cross-linked (50 mJ) in a Stratagene UV cross-linker. Cy-3-and Cy-5-labeled first-strand cDNA probes were prepared from either 15 g total RNA or 0.5 g mRNA from treated and untreated 3T3-L1 cells. The RNA was incubated with 1 g anchored oligo-dT primer at 70°C for 10 min and subsequently chilled on ice for 30 s. The primer-annealed RNA was incubated with reaction mixture (1 ϫ Superscript II buffer; Life Technologies), 10 mmol/l DTT, 200 mol/l dGAT(TP), 100 mol/l dCTP, 100 mol/l Cy-3/Cy-5-dCTP (Amersham Pharmacia Biotech, Buckinghamshire, U.K.), and 200 units Superscript II reverse transcriptase (Life Technologies) at 42°C for 2 h and 30 min in a final volume of 20 l. The RNA template was removed by alkaline denaturation (incubation with 2 l of 2.5 mol/l NaOH at 37°C for 15 min.). Labeled probes were purified on GFX spin columns (Amersham Pharmacia Biotech, Uppsala, Sweden). The Cy-3-and Cy-5-labeled cDNAs were mixed 1:1 in hybridization buffer (version 2; Amersham Pharmacia Biotech, Buckinghamshire, U.K.) and subsequently 1:1 in formamide (Sigma). The mixed probes were injected into an automated slide processor (Amersham Parmacia Biotech) holding the spotted slide and hybridized at 42°C for 16 h. After hybridization, the slide was washed in 1 ϫ sodium chloride-sodium citrate (SSC) and 0.2% SDS at 55°C for 10 min and then in 0.1 ϫ SSC and 0.2% SDS at 55°C for 10 min. The slide was scanned in a Generation III microarray laser scanner (Molecular Dynamics). Image analyses were performed with ArrayVision (Imaging Research). All ratios were calculated using backgroundsubtracted, artifact-removed median densities. The Cy-3-and Cy-5-signals were normalized to the ribosomal phosphoprotein 36B4. Northern blot Analysis. Total RNA was isolated from 3T3-L1 cells using RNA-Zol following the vendor's instructions. 20 g RNA was size-fractionated in a denaturing gel containing 1% agarose, 20 mmol/l MOPS, 5 mmol/l NaOAc, 6% formaldehyde, and 1 mmol/l EDTA, transferred to a Hybond N ϩ membrane (Amersham Pharmacia Biotech) by capillary blotting, and immobilized by UV cross-linking. cDNAs from differential display-isolated fragments were labeled with a Prime It kit (Stratagene, Aarhus, Denmark) using [␣-
32 P]dATP (3,000 Ci/mmol; Amersham Pharmacia Biotech) and hybridized using Express Hyb (Clontech, Stockholm, Sweden) following the manufacturer's instructions, and results were visualized by autoradiography. Quantitative PCR. Total RNA isolated from 3T3-L1 cells were DNase treated, and three reverse transcription reactions were performed using Superscript II reverse transcriptase (Gibco-BRL) following the manufacturer's instructions. mRNA expression levels were analyzed by real-time fluorescent detection using a Lightcycler (Roche) and the following primer combinations: 5Ј-CAGTCCCTCTTAACATGTAAGAC-3Ј and 5Ј-TACAGGATATTCCTTTAGTGGT GG-3Ј for the transducer of erbB-2; 5Ј-CCTGCCTCGCCCTTATCCAAAGC-3Ј and 5Ј-TGGCTAGCTAGTTCAGACATATAC-3Ј for drm; 5Ј-GACAGTCAGTGG TAGGCATGTGAC-3Ј and 5Ј-CAATTCAAATAGTCCTTACCTCCC-3Ј for novel mRNA from the rennin-expressing kidney tumor cell line; 5Ј-CGGTAGTGAC CAGCAAGAGG-3Ј and 5Ј-CAGTACAGAAGGAAAACCACC-3Ј for the TIS11 primary response gene; and 5Ј-TGTCCCAAGGTGTACCCCAGC-3Ј and 5Ј-GG AAGATAAAGGTAGCACTTT-3Ј for Tax binding protein (TXBP181). Expression levels were normalized to the expression levels of 18S as described by the vendor (Applied Biosystems). In vivo studies. ob/ob mice at the age of 10 weeks were divided into groups of six animals and dosed once daily for 16 days with rosiglitazone (100 mg ⅐ kg Ϫ1 ⅐ dose Ϫ1 ) or vehicle (0.5% carboxymethylcellulose) by oral gavage. At the end of the dosing period, animals were killed by decapitation, and then liver, muscle, and WAT was removed and frozen in liquid nitrogen, and RNA was isolated by RNAZol (BioSite, Tä by, Sweden) according to the manufacturer's instructions. RNA from all animals in each group was pooled. All animal experiments were conducted in accordance with Danish law.
RESULTS
Isolation of genes regulated by TZDs during differentiation of 3T3-L1 cells. To identify genes regulated by TZDs in developing adipocytes, we treated 3T3-L1 cells with Dex, insulin, and rosiglitazone and used mRNA differential display analysis to isolate differentially regulated cDNAs. The differential display analysis was performed using total RNA isolated from 3T3-L1 cells at three different time points: 1) from cells 2 days postconfluence (referred to as day 0), 2) from cells treated for 1 day, and 3) from cells treated to differentiate for 7 days. As shown in Table 1 , the differential display analysis resulted in the identification of 132 unique differentially expressed cDNAs. Of these 132 cDNAs, 81 were identical to sequences in public databases encoding proteins with known function, and 34 were homologous to express sequence tags (ESTs), whereas 17 had no significant homology to any known gene or EST available in the databases (Tables 1  and 2 ).
As shown in Table 2 , the genes encoding proteins of known function could be divided into a variety of groups, including: 1) proteins involved in synthesis, degradation, and transport of lipids; 2) secreted proteins; 3) proteins involved in cytoskeleton and extracellular structure; 4) transcription factors and transcription repressors; 5) proteins involved in cell growth control; 6) RNA-interacting proteins; 7) proteins involved in oxidative phosphorylation; 8) proteins important for binding and metabolization of drugs and radicals; and 9) proteins involved in amino acid metabolism. Several of these genes were expected to be regulated because the cells differentiate from fibroblasts to mature adipocytes, and several genes have previously been identified as differentially expressed during the adipocyte differentiation process (Table 2 ) (31-34), confirming the validity of our methods. Among the differentially regulated genes involved in lipid metabolism, we found genes whose products are required for the pyruvate/ malate cycle (including tricarboxylate carrier and malate dehydrogenase), genes encoding proteins involved in the TCA cycle (e.g. citrate synthase and NAD ϩ -dependent isocitrate dehydrogenase subunits 3 and 4), and genes encoding proteins involved in conversion of fatty acids (e.g., steaoryl-CoA desaturase 1 and peroxisomal acyl-CoA oxidase as well as inorganic pyrophosphatase, involved in the hydrolysis of PP i (inorganic pyrophosphate) formed by acyl-CoA synthetase). Furthermore, several genes that have been suggested to be involved in the control of the proliferative state of cells were downregulated, such as metastatic cell protein, drm (downregulated in mos-transformed cells), a 21-kDa peptide that is under translational control in tumor cells, hydrophobic nucleolar protein (HNP36), a large subunit of transforming growth factor (TGF)-␤ masking protein, gas 1 (growth-arrest specific gene 1), and a polypeptide having biological activity relating to proliferation and propagation of cells. This is, in most cases, well in agreement with previous findings indicating that differentiation of 3T3-L1 cells involves growth arrest (35) and that ligand-activated PPAR-␥ is sufficient to induce growth arrest (36) . However, the downregulation of the large subunit of TGF-␤ masking protein, which neutralizes the activity of TGF-␤1, is surprising because TGF-␤1 has previously been shown to inhibit adipocyte differentiation (37) . Similarly, the downregulation of gas 1 is unexpected because this gene has previously been reported to be downregulated during the clonal expansion phase of 3T3-L1 cells (38) . Interestingly, several of the genes encoded mitochondrial and peroxisomal proteins (see Table 2 ), organelles that among other things are responsible for fatty acid catabolism, suggesting that the differentiated 3T3-L1 cells have increased metabolic levels.
Taken together, these changes in gene expression suggest that differentiation of 3T3-L1 cells from fibroblast to mature adipocytes (as induced by treatment with Dex, insulin, and rosiglitazone) involves cessation of cell proliferation; cytoskeleton and extracellular structure changes; changes in the secondary structure of RNA; the capability to metabolize drugs and radicals; and an increased uptake, storage, and conversion of fatty acids. Rosiglitazone regulates genes during adipocyte differentiation, whereas a PPAR-␥ antagonist has no effect in fully differentiated adipocytes. Previous studies have shown that a considerable fraction of 3T3-L1 cells can differentiate into adipocytes in the presence of Dex and insulin alone (39) . However, a remarkably more pronounced differentiation of the 3T3-L1 cells was obtained by the use of a differentiation mixture containing a combination of Dex, insulin, and rosiglitazone (data not shown). Being interested in TZD-regulated gene expression patterns, we sought to identify genes regulated specifically by rosiglitazone during the course of adipocyte differentiation. To do this, we omitted rosiglitazone from the mixture of differentiation reagents (day 7Ϫ), and using cDNA microarray technology, we compared the pattern of gene expression with that of cells treated with the full complement of compounds (day 7ϩ). The cDNA microarray technique was based on immobilization of the isolated cDNAs on glass plates followed by hybridization with fluorescently labeled first-strand cDNAs synthesized from day 7Ϫ and day 7ϩ total RNA. In parallel experiments, we performed cDNA microarray analyses in which we analyzed the changes in gene expression in undifferentiated cells (day 0) and cells differentiated for 7 days with all compounds (day 7ϩ). As shown in Tables 2 and 3 , the differential expression of 50 of the 81 isolated cDNAs encoding proteins of known function could be verified to be regulated Ն2.5-fold during the differentiation process. For ϳ50% (21 of 50) of these cDNAs, the differential expression seemed to be caused or accelerated by the presence of rosiglitazone, whereas the up-or downregulation of the remaining cDNAs could be attributed to the treatment with Dex and insulin alone (Tables 2 and 3) .
Another way of studying the importance of TZDs in adipocytes is the use of antagonists of their receptors. Therefore, we analyzed the effects of a full PPAR-␥ antagonist, LG100641 (12) , in mature adipocytes. 3T3-L1 cells were differentiated for 7 days with Dex, insulin, and rosiglitazone, after which rosiglitazone was exchanged with the PPAR-␥ antagonist, and the cells were treated for an additional 2 days. RNA from these cells was isolated, and the pattern of gene expression was compared with that of cells treated for 9 days with Dex, insulin, and rosiglitazone. However, according to cDNA microarray analyses, no genes were induced or reduced more than 2.5-fold, indicating that the PPAR-␥ antagonist had no Figure 1A and B shows the differential regulation of selected genes such as aP2, adenine nucleotide translocase, metastatic cell protein, and FSP27 according to the conventional reverse Northern blot analysis and DNA microarray analysis, respectively.
To further confirm the results obtained by differential display, reverse Northern blot, and microarray analyses, we performed Northern blot analyses of 13 selected clones ( Fig. 2A) . Genes such as fos-related antigen 1, inorganic pyrophosphatase, VL30, and Cu-Zn-superoxide dismutase, in agreement with reverse Northern analyses, required the presence of all three components of the differentiation cocktail to be upregulated, whereas G-rich sequence factor 1, cytochrome C oxidase polypeptide II, adenine nucleotide translocase 2, immunophilin FKBP51, and NADHubiquinone oxidoreductase chain 4 were upregulated by Dex and insulin alone ( Table 2 , column 2). Among the downregulated genes, metastatic cell protein, in agreement with the results obtained by reverse Northern blot, was downregulated by Dex and insulin alone, whereas an increased downregulation was observed in the presence of all components. Two other downregulated genes, pentylenetetrazole-related cDNA PTZ-17 and a polypeptide having biological activity relating to the proliferation and propagation of cells, were correctly found to be downregulated by treatment with Dex, insulin, and rosiglitazone. However, in contrast to the results obtained by reverse Northern blot, suggesting no effect of rosiglitazone, Northern blot analyses showed that Dex and insulin alone did reduce the expression of these genes, but that maximal downregulation was only observed by the presence of rosiglitazone. Besides the Northern blot analyses of these 13 genes, we performed real-time PCR analyses to quantify the expression of five genes: transducer of Erb-2, novel mRNA from rennin-expressing kidney tumor cell line, drm (downregulated in mos-transformed cells), TIS11 primary response gene, and tax binding protein (TXBP181), which were all found not to be regulated or to be below the detection levels of reverse Northern blot and microarray analyses (Fig. 2B ). All of these selected genes were up-or downregulated in agreement with the data obtained by differential display analyses. When combined, the Northern blot and real-time PCR analyses of 18 genes show that all genes were up-or downregulated as predicted by differential display, indicating that our differential display analyses resulted in the identification of genes that are truly differentially expressed during adipocyte differentiation. TZDs regulate gene expression in vivo. A variety of experiments have shown that differentiation of 3T3-L1 preadipocytes faithfully mimics the process of adipocyte differentiation in vivo, resulting in cells that possess many biochemical and morphologic characteristics of adipocytes (40, 41) . However, the 3T3-L1 model system is limited by the fact that it lacks the endocrine and paracrine interactions between the different cell types found in animals. Therefore, we decided to study the effect of rosiglitazone on adipose tissue in vivo. To test whether cDNAs isolated by differential display from 3T3-L1 cells were also differentially regulated in vivo, we used the conventional reverse Northern blot technique to compare the gene expression of adipose tissue from vehicle-fed ob/ob mice with that of ob/ob mice treated with rosiglitazone. Tables 2 and 3 show that many of the cloned cDNAs that were regulated in 3T3-L1 cells were also regulated in adipose tissue of rosiglitazone-treated animals. In total, 37 of the 81 isolated genes encoding proteins of known function were confirmed by reverse Northern blot analysis to be regulated in adipose tissue of animals treated with rosiglitazone. Among the genes of known function that were verified to be differentially regulated by reverse Northern blot were genes encoding proteins involved in 3T3-L1 cells  7ϩ/0  19  2  11  3  6  1  6  2  50  7ϩ/7Ϫ  13  2  5  1  ----21  AT  29  1  6  -1  ---37  Liver  1  1  ------2  Muscle  6  -2  -1  ---9 the uptake and transport of fatty acids, such as fatty acid transporter, lipoprotein lipase, and aP2 as well as several genes encoding proteins involved in the conversion of fatty acids and metabolites within the adipocytes, such as stearoyl-CoA desaturase 1, peroxisomal acyl-CoA oxidase, and medium-chain acyl-CoA dehydrogenase. Interestingly, several of the regulated proteins were mitochondrial and peroxisomal (Table 2) , which is well in accordance with a recent report illustrating rosiglitazone-induced numbers of mitochondria per cell in WAT of Sprague Dawley rats (42) . Furthermore, we tested whether any of these genes were regulated by the rosiglitazone treatment in the liver and muscle tissues. In contrast to the results obtained from adipose tissue, only very few genes were regulated in the liver, whereas slightly more genes were regulated in the muscle tissues of the animals treated with the insulin sensitizer (Tables 2 and 3 ). Taken together, these findings show that rosiglitazone induces many common genes in the adipose tissue of ob/ob mice and 3T3-L1 cells induced to differentiate with Dex, insulin, and rosiglitazone, whereas only minor effects of rosiglitazone were detected on these genes in muscle and liver.
DISCUSSION
To gain a detailed molecular understanding of the mechanism of action of the TZD class of insulin sensitizers in the process of adipocyte differentiation, we identified genes exhibiting altered expression during the differentiation process driven by the potent TZD rosiglitazone. The model system used for these studies was 3T3-L1 cells, which are mouse embryo fibroblasts that by treatment with Dex, insulin, and TZDs can differentiate into adipocytes. To detect and identify genes that were regulated during differentiation, we chose to use mRNA differential display as a relatively unbiased random approach that does not depend on existing genetic data. In total, we isolated 132 unique cDNAs, of which 81 were identical to genes encoding proteins of known function. Recent studies have shown that an abundance of Ͼ1,200 genes is changed during the differentiation process of 3T3-L1 cells (31, 32, 34) . Comparison of our list of genes encoding proteins of known function (81 genes) with previously identified genes revealed an overlap of 33 genes, strongly suggesting that additional studies have to be conducted to obtain a comprehensive list of genes that are differentially expressed during adipocyte differentiation.
Many novel differentially expressed genes have been isolated in our experiments, most of which were confirmed by other technologies to be truly differentially regulated transcripts. These conclusions were based on the results obtained by two different methods of reverse Northern blot, conventional analysis using 32 P-labeled cDNAs as probes, and the more recently developed method of DNA microarray analysis. By the use of these techniques, 50 of 81 clones encoding proteins of known function were verified to be differentially regulated during the differentiation of 3T3-L1 fibroblasts into adipocytes. Although the remaining 31 clones may potentially be false positives, this is not considered likely when taking the relative sensitivity of the applied methods into account. Much of a cell's mRNA mass consists of many copies of a small number of genes, and 96% of transcripts are estimated to be expressed at Ͻ50 copies per cell (43) . Consistent with this, five clones for which the differential regulation could not be confirmed by reverse Northern blot techniques turned out to be truly regulated clones when analyzed by real-time PCR analyses. Several of the remaining 26 clones are therefore likely low-abundance messages that are true positives but simply not detectable above background in the cDNA microarray and reverse Northern blot assays. Because mRNA differential display analysis is inherently a very sensitive technique allowing for the detection of genes expressed at highly varying levels, it is expected (and desired) to identify some transcripts that cannot be found or analyzed for using Northern technologies. Therefore, this study is likely to have uncovered novel regulated transcripts that would be hard to find using, for example, DNA chip/microarray approaches.
The differentiation protocol involving the use of a combination of Dex, insulin, and rosiglitazone resulted in the identification of genes specifically regulated or enhanced/ reduced by TZDs, but it also identified genes regulated by Dex and insulin alone. To identify genes exhibiting altered expression specifically caused by rosiglitazone, we compared gene expression levels in 3T3-L1 cells differentiated using a combination of Dex and insulin alone with cells differentiated using all three components. Microarray analyses revealed that the differential expression of ϳ50% of the genes of known function (21 of 50 reverse Northernverified genes) was caused by or accelerated by rosiglitazone. In contrast to these findings, during the process of differentiation, the PPAR-␥ antagonist LG100641 (12) had no or very weak effects on the pattern of gene expression in fully differentiated 3T3-L1 cells. These observations are in good agreement with a recent report using another PPAR-␥ antagonist, which had no effect on the morphology and basal lipolysis status in mature adipocytes (11) . Although it has been observed that TZDs can downregulate PPAR-␥ itself (44), we did observe a high expression of PPAR-␥ in fully differentiated 3T3-L1 cells (data not shown), suggesting a potential for effects of a full antagonist. To our knowledge, the data presented here are the first illustrating the lack of effect of a PPAR-␥ antagonist as detected in a large number of genes in fully differentiated adipocytes. Another study has demonstrated a reduced expression of selected proteins such as fatty acid translocase in WAT of high fat-fed KKA y mice in response to other PPAR-␥ antagonists (26) , and these antagonists were suggested to prevent adipocyte hypertrophy. The reasons for differences between our results and those of Yamauchi et al. (26) are at present not clear, although it is tempting to speculate that endocrine and paracrine factors present in the in vivo settings (e.g., leptin) are playing an important role.
Interestingly, the differential regulation of the genes found by differential display analysis of differentiating 3T3-L1 cells was shown in many cases to also occur in WAT of ob/ob mice treated with rosiglitazone (37 of 81 genes encoding proteins of known function). This is well in agreement with recent reports demonstrating TZDinduced differential regulation of a variety of genes in WAT of other diabetic animal models, such as Zucker diabetic fatty rats and db/db mice (28, (45) (46) (47) . However, comparison of our 37 reverse Northern-verified genes with these genes revealed an overlap of only 7 genes. Our results therefore add a significant number of novel genes, which are transcriptionally regulated by TZDs in WAT. The differential expressions of genes in the adipose tissue of ob/ob mice is likely to stem from differentiation of preexisting preadipocytes within the adipose tissue or occur in mature adipocytes or both. The pronounced overlap of genes differentially regulated in vivo and in vitro suggests that rosiglitazone induces in vivo adipocyte differentiation in ob/ob mice. This is consistent with previous reports demonstrating that other insulin sensitizers, such as pioglitazone and troglitazone, increase the number of smallsized adipocytes and stimulate the expression of genes involved in the lipid metabolism of adipocytes in obese Zucker rats (27, 28) . Combined with the lacking effect of the PPAR-␥ antagonist in fully differentiated adipocytes in vitro, our data therefore suggest that the beneficial effect of TZDs in vivo may be caused by an increased differentiation of preadipocytes within the adipose tissue. It is important to note, though, that the present analyses are based on a fraction of genes, and the existence of other genes (such as CAP) (48) specifically regulated by TZDs in mature adipocytes cannot be excluded to play important roles.
A few discrepancies were observed between the results obtained by the use of 3T3-L1 cells and the use of adipose tissue from ob/ob mice. First, some genes were verified as differentially regulated by reverse Northern blot analysis in vivo but not in vitro (e.g., medium-chain acyl-CoA dehydrogenase, fos-related antigen 1, tricarboxylate carrier, ras like rap 1B, serine-rich RNA polymerase suppressor protein-1, PK-120 precursor [itih-4], and osteoblast-specific factor 2). One explanation for these findings could be a combination of different expression levels in vitro and in vivo and the limitations of the reverse Northern blot technique. Previous studies have shown that some genes are expressed at high levels in vivo and are absent or expressed at lower levels in vitro (31) . Second, a few genes seemed to be regulated in one direction in 3T3-L1 cells and regulated in the opposite direction in the adipose tissue of rosiglitazone-treated ob/ob mice. ␣1 Type I procollagen, metastatic cell protein, a large subunit of TGF-␤ masking protein, osteoblast-specific factor 2, tax binding protein TXB181, novel mRNA from the rennin-expressing kidney tumor cell line, and pentylenetetrazole-related cDNA PTZ-17 were all found to be downregulated in 3T3-L1 cells during the differentiation process but upregulated in the adipose tissue of rosiglitazone-treated animals. There is no evident explanation for these differences, but, speculatively, different requirements may exist for the formation of cytoskeleton and extracellular structure during the process of adipocyte differentiation in vitro compared with the in vivo situation, explaining the opposite regulation of some genes such as the ␣1 type I procollagen. The increased expression in vivo of the large subunit of TGF-b masking protein, which neutralizes the activity of TGF-␤1, is well in agreement with the expected reduced proliferation of cells undergoing differentiation. The significance of the surprisingly reduced expression of the large subunit of TGF-␤ masking protein in vitro remains to be elucidated.
Moreover, our results show that rosiglitazone has considerably larger effects on the expression of the selected genes in adipocytes compared with liver and muscle tissues. This is well in agreement with the low expression in these tissues of PPAR-␥, which is considered to be the receptor for the TZDs. It should be noted, though, that our analysis is biased toward adipose-specific genes and as such may not reflect the full picture of PPAR-␥ agonist action. In the liver, we only detected upregulation of two transcripts encoding proteins of known function, one of which was identified as aP2, perhaps caused by a minor contamination of the liver samples with macrophages. We do not expect interference with PPAR-␣ because no induced expression of fatty acid transporter was seen in the liver, which has previously been demonstrated to be induced by PPAR-␣ activators (6) . In the muscle tissue, we identified a few extra differentially expressed genes. A previous nonbiased analysis has shown that another TZD, GW1929, in muscle tissue of Zucker diabetic fatty rats decreases the expression of pyruvate dehydrogenase 4 as well as other genes involved in fatty acid transport (45) . Combining these results, it is therefore tempting to speculate that the observed effects of TZDs might be a pleiotropic response. First, it is plausible that it involves differentiation of novel active adipocytes in the adipose tissue, resulting in increased uptake and conversion of fatty acids by the adipose tissue with a concomitant reduction of the level of free fatty acids in the plasma, thereby-in accordance with the Randle cycle (49)-leading to increased insulin sensitivity in other peripheral tissues, such as liver and muscle. Second, it is possible that TZDs induce/reduce specific responsive genes in all tissues involved in glucose metabolism.
In summary, the differential display analysis of 3T3-L1 cells differentiating to adipocytes by the treatment with Dex, insulin, and the potent insulin sensitizer rosiglitazone has resulted in the identification of a variety of novel genes that are differentially regulated during the course of TZDinduced differentiation. The expression levels of several genes were specifically regulated or enhanced/reduced by rosiglitazone during the course of differentiation, whereas a specific PPAR-␥ antagonist had no effect in terminally differentiated adipocytes in vitro. Furthermore, most of the identified genes were confirmed to be regulated in adipocytes of ob/ob mice treated with rosiglitazone, and our results therefore support the notion, on the molecular level, that TZDs activate PPAR-␥ in the adipose tissue, resulting in differentiation of preexisting preadipocytes found among the mature adipocytes in adipose tissue.
